Project
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Completed · 2020 until 2024
Jörger Markus, Demmer-Steingruber Ruth, Quinter Janine